ipharmacenter Consulting services

FDA approved Imfinzi for perioperative use The U.S. FDA approved Imfinzi (durvalumab) as the first and only perioperative immunotherapy for adults with resectable stage II–IVA gastric and gastroesophageal junction (GEJ) cancers, in combination with FLOT chemotherapy before surgery, continued with FLOT plus Imfinzi after surgery, and followed by Imfinzi monotherapy. The decision was granted Priority Review and evaluated under the FDA’s Project Orbis framework, enabling coordin

BEST SELLING CANCER DRUGS | TOP ONCOLOGY DRUGS | 2025 Rank Brand Revenues 1 Keytruda $ 23.3 billion 2 Darzalex $ 10.4 billion 3 Opdivo $ 7.4 billion 4 Tagrisso $ 5.4 billion 5 Imfinzi $ 4.3 billion 6 Verzenio $ 4.1 billion 7 Kisqali $ 3.5 billion 8 Tecentriq $ 3.3 billion 9 Ibrance $ 3.0 billion 10 Perjeta $ 2.9 billion In 2025, global oncology revenues continue to be dominated by immune checkpoint inhibitors and targeted therapies, with Merck’s PD‑1 inhibitor Keytruda far ah